Email Updates

You are here

MDP 301

Status
Completed
Phase
III
Principal Investigator(s)
Sheena McCormack
Objective

To determine the efficacy and safety of 0.5% and 2% PRO 2000/5 gels in preventing vaginally acquired HIV infection

Prevention Option(s)
Microbicides
Study Design
Controlled
Randomized
Double-blind
Arms and Assigned Interventions
Mode of Delivery
Gel
ARMs
Placebo Comparator
Description
0.5% gel
Mode of Delivery
Gel
Products
Pro 2000/5 gel
ARMs
Experimental
Trial Sponsors
Endo Pharmaceuticals
Product Developers
Medical Research Council, DFID
October 2005
September 2009
Enrollment
9 404
16
Years
Population
Women
Sites

Site(s) - Zambia

Swinazongwe District
Zambia

Site(s) - Uganda

Uganda

Site(s)- South Africa

South Africa